Mathematical predictions followed by experimental studies demonstrated that otherwise TRAIL-resistant GBM cells respond synergistically towards combinations of TRAIL/TL32711 in presence of Bcl-2 antagonist ABT-199, indicating the need for triple treatment combinations (Fig. 6f). The gene discussed is BCL2; the disease is glioblastoma.